Nikhil Wagle
Broad Institute · 602 works · 22,320 citations · h-index 61
Top works
- A Landscape of Driver Mutations in Melanoma
- Melanoma genome sequencing reveals frequent PREX2 mutations
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
- Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
- A p53-Dependent Checkpoint Pathway Prevents Rereplication
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF -Mutant Colorectal Cancer through MAPK Pathway Alterations
- A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
- Assessing the clinical utility of cancer genomic and proteomic data across tumor types
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma